KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Free Cash Flow (2016 - 2025)

Travere Therapeutics' Free Cash Flow history spans 15 years, with the latest figure at $60.7 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 269.87% year-over-year to $60.7 million; the TTM value through Dec 2025 reached $37.6 million, up 115.85%, while the annual FY2025 figure was $37.8 million, 115.91% up from the prior year.
  • Free Cash Flow reached $60.7 million in Q4 2025 per TVTX's latest filing, up from $14.2 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $60.7 million in Q4 2025 to a low of -$119.0 million in Q1 2024.
  • Average Free Cash Flow over 5 years is -$43.4 million, with a median of -$41.1 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: surged 632.93% in 2021, then tumbled 675.99% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at -$88.5 million in 2021, then increased by 13.27% to -$76.7 million in 2022, then crashed by 50.96% to -$115.8 million in 2023, then surged by 69.16% to -$35.7 million in 2024, then skyrocketed by 269.87% to $60.7 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Free Cash Flow are $60.7 million (Q4 2025), $14.2 million (Q3 2025), and $5.0 million (Q2 2025).